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Therapeutic tolerance to self-antigens or foreign antigens is thought to depend on con-
stant vigilance by Foxp3+ regulatory T cells (Tregs). Previous work using a pancreatic 
islet allograft model and a short pulse of CD3 antibody therapy has shown that CD8+  
T cells become anergic and use TGFβ and coinhibitory signaling as their contribution to 
the tolerance process. Here, we examine the role of CD4+ T cells in tolerization by CD3 
antibodies. We show that both Foxp3+ Tregs and CD4+ T cell anergy play a role in the 
induction of tolerance and its maintenance. Foxp3+ Tregs resisted CD3 antibody-me-
diated depletion, unlike intragraft Th1 CD4+ lymphocytes coexpressing granzyme B 
and Tbx21, which were selectively eliminated. Tregs were mandatory for induction of 
tolerance as their depletion at the time of CD3 antibody therapy or for a short time 
thereafter, by an antibody to CD25 (PC61), led to graft rejection. Early treatment with 
CTLA-4 antibody gave the same outcome. In contrast, neither PC61 nor anti-CTLA-4 
given late, at day 100 posttransplant, reversed tolerance once established. Ablation of 
Foxp3 T cells after diphtheria toxin injection in tolerant Foxp3DTR recipient mice provided 
the same outcome. Alloreactive T cells had been rendered intrinsically unresponsive as 
total CD4+ or Treg-deprived CD4+ T cells from tolerant recipients were unable to mount 
donor-specific IFN-γ responses. In addition, intragraft Treg-deprived CD4+ T cells lacked 
proliferative capacities, expressed high levels of the inhibitory receptor PD-1, and exhib-
ited a CD73hiFR4hi phenotype, thus reflecting a state of T cell anergy. We conclude that 
Tregs play a substantive and critical role in guiding the immune system toward tolerance 
of the allograft, when induced by CD3 antibody, but are less important for maintenance 
of the tolerant state, where T cell anergy appears sufficient.
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inTrODUcTiOn
Manipulating the immune system to induce immune tolerance has been the focus of numerous 
studies in transplantation aiming to promote long-term graft survival and to minimize immuno-
suppressive drugs with their attendant unwanted side effects. Lessons gathered from experimental 
models using monoclonal antibodies (Abs), or fusion proteins directed against T cell receptor (TCR) 
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coreceptors (CD4 and CD8) and/or costimulatory molecules 
(CD28 and CD40L), have unanimously highlighted the central 
role of CD4+Foxp3+ regulatory T cells (Tregs) in controlling 
alloreactive effector T cells (Teff) and thus promoting transplant 
tolerance and long-term graft survival (1–3). Tregs, operating 
through mechanisms of linked suppression (tolerance to one set 
of antigens extended to other antigens coexpressed in the same 
tissue) and infectious tolerance (generation of new peripher-
ally derived Tregs (pTreg) specific for the original antigen), are 
thought to be required at both the induction and maintenance 
phases of tolerance (4–6). Transgenic models of transplantation 
using CD4 and CD8 Abs have emphasized the induction of 
Foxp3+ pTreg, which can actively and continuously control Teff 
within the graft microenvironment, creating a form of immune 
privilege (6–8).
We previously established, in experimental models aim-
ing to reverse autoimmune disease and enable acceptance 
of transplants, that CD3 Abs possess tolerance promoting 
properties (9). In particular, we reported that non-Fc-binding 
CD3 F(ab′)2 fragments, administered in a defined therapeutic 
window, induced long-term survival of fully MHC-mismatched 
cardiac and pancreatic islet transplantation and implantation of 
allogeneic stem cells (10–12). Long-term acceptance of second 
grafts from the original, but not third-party donors, proved 
that antigen-specific tolerance had been induced (10). We have 
previously shown that alloreactive CD8+ T cells become anergic 
within anti-CD3 tolerized mice and use TGFβ and coinhibitory 
signaling as their contribution to the tolerance process (13). 
Our previous work revealed that Foxp3+ Tregs accumulated 
within the grafts of CD3 Ab-treated mice. However, the role 
of Tregs in the induction and/or the longevity of tolerance was 
not investigated. Here, we now show that CD4+Foxp3+ Tregs, 
spared from depletion by CD3 Ab, are crucial for the induc-
tion of transplant tolerance, whereas other alloantigen-specific 
CD4+ T cells become anergic, as was the case for CD8+ T cells 
(13). We conclude that Treg may be relatively dispensable for 
tolerance maintenance, which predominantly manifests itself 
as T cell anergy.
MaTerials anD MeThODs
Mice
C57BL/6, RAG−/− C57BL/6, and BALB/c mice were bred in our 
facility under specific pathogen-free conditions. Foxp3DTR mice 
were a gift from D.A. Gross (INSERM U1151, Paris). Blood glu-
cose was measured using ACCU-CHECK Performa glucometer 
(Roche Diagnostics). Experiments were conducted according to 
European Directives (2010/63/UE) and were approved by the 
Ethical Committee of Paris Descartes University (#14-075) and 
the French Ministry of Education and Research (#04462.02).
Pancreatic islet isolation and 
Transplantation
Pancreatic islets were separated by density gradient centrifuga-
tion (Histopaque, Sigma-Aldrich) after in situ digestion with col-
lagenase P (Roche Applied Science) and transplanted (300 islets) 
under the kidney capsule of diabetic recipients. Diabetes was 
induced by a single injection of streptozotocin (Sigma-Aldrich) 
at 225 mg/kg. Diagnosis of graft rejection was made after three 
glucose measurements >250 mg/dl.
abs and In Vivo Treatments
The cell line SP2/0 producing the genetically engineered 145-
2C11 F(ab′)2 fragments (14) as well as the CTLA-4 Ab (4F10) 
were provided by J. A. Bluestone (UCSF, San Francisco, CA, 
USA). CD3 F(ab′)2 fragments were injected i.v. at the dose of 
50 μg/day for 5 days, starting on day 7 posttransplant as previously 
described (10). Purified anti-CTLA-4 Abs were injected i.p. at the 
dose of 500 μg/day. Purified CD25 Abs (PC61, Bio X Cell) were 
administered at the dose of 300 μg i.p. For flow cytometry, CD4 
(GK1.5), CD8 (53-6.7), TCR Vβ (H57-597), CD44 (IM7), CD62L 
(MEL-14), CD69 (H1.2F3), CD122 (TM-β1), CTLA-4 (4F10-11), 
and Ki67 (B56) Abs were purchased from BD Biosciences and 
Foxp3 (FJK-16S), FR4 (ebio12A5), CD73 (ebioTY/11.8) and 
PD-1 (RMP1-30) Abs purchased from eBioscience.
Diphtheria toxin (DT) (gift from D. A. Gross, INSERM U1151, 
Paris) was injected i.p. at the dose of 25 μg/kg for two consecutive 
days in transplanted Foxp3DTR recipient mice showing established 
tolerance after CD3 Ab therapy.
iFn-γ elisPOT
The method has been previously described (15). Briefly, PVDF 
plates were coated with anti-IFN-γ Ab (U-Cytech). Purified CD4+ 
T cells (105/well) were incubated with 105 irradiated splenocytes 
from C57BL/6, BALB/c, or C3H mice. After a 20-h culture, IFN-γ 
was detected using biotinylated anti-IFN-γ Ab, streptavidin-
horseradish peroxidase, and SigmaFAST NBT-BCIP (Sigma-
Aldrich). Results were expressed as spot-forming units/106 cells.
In Vitro suppression assays
Effector T cells were obtained by immunizing C57BL/6 mice 
with BALB/c antigens (30 × 106 spleen cells i.p. on day 20 and 
day 10). T cells were isolated by magnetic sorting (T cell isola-
tion kit, Miltenyi Biotec), labeled with the violet proliferation 
dye (VPD450), and coincubated at a 1/1 ratio with CD4+CD25+ 
Tregs (5 × 104 cells/well) isolated from transplanted recipients 
(treated or not with CD3 Abs). Cells were stimulated with T 
cell-depleted irradiated splenocytes from BALB/c mice for 
5 days. Proliferation was evaluated by flow cytometry by gating 
on CD8+ Teff among living cells. In parallel experiments, cells 
were stimulated with mitogenic CD3 Abs (145-2C11, 2 μg/ml). 
When needed, CTLA-4 Abs were added at the dose of 20 μg/ml 
on day 0.
single-cell Pcr
Individual CD4+ T cells were FACS sorted from the spleen or the 
islet allografts of untreated or CD3 Ab-treated recipients. After 
cell lysis by heating/cooling steps, RNA was specifically retrotran-
scribed using MuLV Reverse Transcriptase (Applied Biosystems) 
and 3′ specific primers (Eurofins MWG). The resulting cDNA 
was next amplified (first PCR with all primers). Product of this 
first PCR was then subjected to a second PCR using SYBR Green 
PCR Master Mix (Applied Biosystems) for each primer pairs. 
FigUre 1 | Foxp3+ regulatory T cells (Tregs) resist cD3 antibody (ab)-induced depletion. Spleen, draining renal lymph nodes (dLN), and islet allografts were 
recovered on day 14 or 100 after transplantation from C57BL/6 mice treated or not with CD3 Abs (treatment at day 7 posttransplant for 5 consecutive days). Foxp3 
expression was evaluated in the CD4+ T cell population (a) and in the total lymphoid gate (B) (black symbols: untreated; gray symbols: CD3 Ab-treated).  
(c) Number of Foxp3+ regulatory and Foxp3− effector CD4+ T cells present within the islet allograft before and after CD3 Ab therapy (gray area). (D) Percentage of 
cell depletion evaluated in CD4+Fox3− T cells or in CD4+Foxp3+ T cells after treatment with CD3 Abs (*p < 0.02, **p < 0.002, and ****p < 0.0001).
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To ensure that each well contained a T cell, Cd3e mRNA was 
amplified simultaneously with the genes of interest. HPRT was 
the housekeeping gene. Multiplex single-cell PCR was performed 
for the following genes: granzymes A and B (Gzma, Gzmb), 
perforin-1 (Prf1), and FasLigand (Fasl), which provide killing 
abilities; the transcription factors T-bet (Tbx21) and the β chain 
of the IL-12 receptor (Il-12rb), which promote IFN-γ expression; 
and the killer cell lectin-like receptor G-1 (Klrg1), which marks 
terminally differentiated Teff.
statistics
Cumulative actuarial graft survival was calculated using the 
Kaplan–Meier method. The statistical comparison was performed 
using the log-rank (Mantel-Cox) test. When appropriate, Mann–
Whitney, Student’s t-test (paired or unpaired), or Chi square (χ2) 
test was used. A p value <0.05 was considered significant.
resUlTs
Foxp3+ Tregs resist cD3 ab-induced 
Depletion and are Mandatory for 
Tolerance induction
We previously reported that short-course treatment with CD3 
Ab F(ab′)2 fragments induced long-term survival and immune 
tolerance toward fully mismatched pancreatic islets (10). Here, 
we investigated the impact of CD3 Ab treatment on Foxp3+ 
Tregs and their role in tolerance induction. C57BL/6 mice, 
rendered diabetic after one injection of streptozotocin, were 
transplanted with pancreatic islets from BALB/c mice and 
were treated on day 7 and for 5 consecutive days with CD3 
Ab F(ab′)2. Analysis of CD4+ T cells on day 14 posttransplant 
revealed after CD3 Ab treatment a significant increase in the 
proportion of CD4+Foxp3+ T cells, not only in secondary 
lymphoid organs [spleen: 14.9 ± 0.7 vs 29.2 ± 0.9%, draining 
renal lymph nodes (dLN): 18.4 ± 0.8 vs 41.1 ± 1.7%] but also 
in the islet allografts (23.2 ± 1.3 vs 41.2 ± 1.6%) (Figure 1A). 
However, this was not due to a substantial systemic expansion 
of Tregs since the frequency of Foxp3+ T cells within the total 
lymphoid population was not significantly modified after CD3 
Ab therapy (Figure  1B). Indeed, CD3 Ab preferentially tar-
geted CD4+Foxp3− T cells as shown by their drastic decreased 
number detected after treatment in the transplanted islets 
where approximately 70% of them were depleted as compared 
to a mean of 8.5% for CD4+Foxp3+ Tregs (Figures 1C,D). On 
day 100 posttransplant, Foxp3+Treg frequencies were back to 
normal in the spleen and dLN, while they were still high within 
the graft (30.2 ± 1.4%) (Figure 1A).
The in  vitro ability of Tregs to inhibit the proliferation of 
VPD450-labeled Teff (recovered from C57BL/6 mice immunized 
with BALB/c antigens) stimulated with irradiated BALB/c APCs 
was evaluated. Tregs from CD3 Ab-treated mice showed a higher 
FigUre 2 | Foxp3+ regulatory T cells (Tregs) exhibit antigen-specific suppressive capacities. (a,B) Co-cultures were established by incubating VPD450-
labeled effector CD8+ T cells (Teff) from C57BL/6 mice immunized with BALB/c antigens with CD4+CD25+ T cells Tregs isolated from transplanted mice treated or 
not with CD3 antibodies (Abs). Cells were plated at a 1/1 ratio and stimulated with T cell-depleted irradiated BALB/c splenocytes (APC) for 5 days.  
(a) Representative histograms of TeffBALB/c proliferation are shown (upper panels) as well as the proportion of TeffBALB/c that divided three times or more and the 
percentage of inhibition of dividing cells (≥3 divisions) in the presence of Tregs (lower panels) (n = 6, *p < 0.04, **p < 0.008). (B) Supernatants were collected after 
72 h of coculture, and the production of IFN-γ by TeffBALB/c in the presence or absence of Tregs was measured by ELISA (n = 6, p < 0.03). Percentage of inhibition of 
IFN-γ production by Tregs is also represented (**p < 0.01). (c) Teff were recovered from C57BL/6 mice previously immunized with third-party antigens (spleen cells 
from NOD mice), labeled with VPD450, and cocultured at a 1:1 ratio with Tregs from untreated or CD3 Ab-treated recipients in the presence of T cell-depleted 
splenocytes from NOD mice. Upper panel: Representative histograms of CD8+ TeffNOD proliferation as measured by VPD450 dilution in the presence or absence of 
Tregs. Lower panel: Proportion of VPD450-labeled TeffNOD that underwent three divisions or more (n = 6) and percentage of inhibition of TeffNOD proliferation cultured 
with Tregs.
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efficacy in inhibiting donor-specific proliferative responses as 
compared to Tregs from untreated recipients: 49.5 vs 31.7% 
inhibition, respectively (Figure  2A). Similarly, IFN-γ produc-
tion by alloreactive T cells was significantly inhibited by Treg 
from CD3 Ab-treated recipients (Figure 2B). Such an outcome 
was not observed when Tregs were cocultured with VPD450-
labeled Teff recovered from C57BL/6 mice immunized with 
third-party (NOD) antigens and stimulated by irradiated NOD 
APCs (Figure 2C). In this situation, Tregs from untreated and 
CD3 Ab-treated mice showed modest yet similar suppressive 
capacities.
Regulatory T cells exerted their suppressive effect in a 
CTLA-4-dependent manner as addition of CTLA-4 binding Abs 
completely reversed the inhibition of VPD450-labeled Teff prolif-
eration (induced by CD3 Abs) (Figure 3A). Of note, expression of 
CTLA-4 after CD3 Ab treatment was almost exclusively restricted 
to Foxp3+ Tregs (Figure 3B).
To further investigate the respective role of Foxp3+ Treg-
mediated suppression, we performed three series of in  vivo 
experiments using CD25 Ab (PC61), which preferentially 
depletes Foxp3+ Tregs. Administration of PC61 at the time of 
CD3 Ab therapy, or 10 days after the end of treatment (when T cell 
compartment was actively reconstituting), abrogated permanent 
graft survival and tolerance induction (Figure 4A). In contrast, 
injection of PC61 on day 110, once tolerance was established, did 
not precipitate graft rejection (Figure 4A). To confirm this last 
result, Foxp3DTR recipient mice were transplanted with BALB/c 
islets, treated with CD3 Abs, and, once tolerant, were injected 
with DT. Although Treg ablation was complete, islet  allografts 
survived in treated mice (Figure  4B). In vivo neutralization of 
CTLA-4 provided identical results to the one obtained with PC61, 
i.e., inhibition of tolerance when CTLA-4 Ab was administered 
early at the time of CD3 Ab treatment but not when given late at 
day 100 (Figure 4C).
FigUre 3 | regulatory T cells (Tregs) involved in tolerance induction express and require cTla-4 to manifest their suppressive function. (a) In vitro 
suppressive capacity of Tregs is CTLA-4 dependent. CD4+CD25+ Tregs were isolated from C57BL/6 mice transplanted with BALB/c islets and treated or not with 
CD3 antibody (Ab). Effector T cells (Teff) were recovered from C57BL/6 mice previously immunized with BALB/c antigens. Teff and Tregs were coincubated at a 1:1 
ratio and stimulated with CD3 Abs (145-2C11) for 5 days. Neutralizing CTLA-4 Abs were added to the culture on day 0. Representative histograms of CD8+ Teff 
proliferation are shown (upper panels) as well as the proportion of CD8+ Teff that divided three times or more and the percentage of inhibition of dividing cells (≥ 3 
divisions) in the presence of Tregs (lower panels) (*p < 0.04, **p < 0.008). (B) Representative dot plots of Foxp3 and CTLA-4 coexpression by spleen, draining lymph 
nodes, or graft-infiltrating CD4+ T cells on day 14 after pancreatic islet transplantation and CD3 Ab therapy (n = 6–12).
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cD3 ab Therapy abrogates anti-Donor 
Th1 responses and induces anergy
Multiplex single-cell PCR was used to approach the gene sig-
nature of individual alloreactive CD4+ T cells in response to 
CD3 Abs. On day 14 posttransplant, we sorted individual CD4+ 
T cells from the islet allografts (72 cells) or spleen (48 cells) of 3 
distinct recipients, treated or not with CD3 Ab, and we analyzed 
the coexpression of Th1 inflammatory and cytotoxic genes 
(Figure  5). In untreated mice, half of graft-infiltrating CD4+ 
T  cells expressed Gzmb and 31% expressed the transcription 
factor Tbx21 (T-bet), the master regulator of Th1 differentiation 
(Figure  5A). Of note, most Tbx21+CD4+ T cells coexpressed 
Gzmb (Figure 5C). Klrg1, which marks differentiated end-stage 
T cells, and Il-12rb were detected within the Tbx21+Gzmb+CD4+ 
T cell subpopulation. Fasl was detected in a fraction of cells and 
was associated, at least in part, with Gzmb. More than 25% of 
intragraft CD4+ T cells coexpressed three or more of the seven 
genes tested (Figure 5B).
CD3 Ab treatment eliminated the Gzmb+Tbx21+CD4+ T sub-
population from the transplanted tissue (Figure 5C). Expression 
of Tbx21 was greatly reduced (from 30.6 to 5.6%) as well as that of 
Gzmb, Il-12rb, and Klrg1 (Figure 5A). Some cells still coexpressed 
Fasl and Gzmb (Figure 5C). The frequency of cells negative for all 
selected genes increased from 18.1% in untreated mice to 43.1% 
in CD3 Ab-treated mice where less than 5% of graft-infiltrating 
CD4+ T cells coexpressed three to four genes (Figure  5B). 
FigUre 4 | induction and maintenance of transplant tolerance engage distinct regulatory mechanisms. C57BL/6 mice were transplanted with BALB/c 
islets and treated with CD3 antibodies (Abs) F(ab′)2. (a) Regulatory T cell (Tregs)-depleting CD25 Ab (PC61) was administered at the dose of 300 μg i.p. at different 
time points: on days 5, 8, and 11 (at the time of CD3 Ab therapy, n = 4), on days 15, 18, and 21 (at the time of T cell reconstitution, n = 5), or on days 113, 116, 
and 119 posttransplant once tolerance was established (n = 5) (***p = 0.0004 and ****p < 0.0001 when comparing CD3 Ab− to CD3 Ab+ PC61-treated mice).  
(B) Foxp3DTR mice were transplanted with BALB/c islets and treated on day +7 with CD3 Abs. Tolerant mice were injected (n = 4) or not (n = 3) with diphtheria toxin 
(DT) at the dose of 25 μg/kg for 2 consecutive days. Treg elimination was analyzed in the blood 48 h after DT injection (*p = 0.027) (left panels), and islet graft 
survival was monitored (right panel). (c) CTLA-4 Ab was injected at the dose of 500 μg, five injections 3 days apart, starting either on day 7 (n = 8) or day 110 
posttransplant (n = 5) (*p < 0.027 between CD3 Ab and CD3 + CTLA-4 Ab-treated mice).
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At the protein level, this translated into a significant decreased 
ability of intragraft CD4+ T cells to produce IFN-γ and IL-2 after 
CD3 Ab therapy (Figure  5D). Multiplex single-cell PCR was 
also performed on day +100 posttransplant and confirmed the 
downregulated gene expression profile of graft-infiltrating CD4+ 
T cells (Figures 5A–C).
In the spleen, Gzmb and Tbx21 were also expressed by CD4+ 
T cells recovered from untreated recipients but were not system-
atically coexpressed by the same cells (Figures  6A–C). Tbx21 
expression was completely abrogated after CD3 Ab treatment.
The phenotypic analysis confirmed the hyporesponsive profile 
of graft-infiltrating CD4+ T cells after CD3 Ab therapy. On day 
14 and up to day 100 posttransplant, although they expressed an 
antigen-experienced CD44highCD62LlowCD69+ phenotype, they 
continually displayed very low expression of the proliferation 
marker Ki67 and CD122 (β chain of IL-2 and IL-15 receptors) 
but high expression of inhibitory receptor PD-1 (Figure 7).
Functional assays (IFN-γ Elispot) were performed to assess the 
donor-specific reactivity of CD4+ T cells at different time points 
after transplantation and treatment. CD4+ T cells from CD3 
Ab-treated mice were unable to mount an efficient IFN-γ response 
toward BALB/c antigens up to day 100 posttransplant, well after 
the Ab had cleared from the blood circulation and T cells were 
back to their normal levels (Figure 8A). In contrast, CD4+ T cells 
from untreated recipients displayed an antigen-specific increase 
of IFN-γ production on day 14 and 21 after transplantation, i.e., 
at the time of rejection.
Analysis of tolerant C57BL/6 recipients (day 100) further 
showed that Treg-depleted CD4+ T cells (CD4+CD25−) were 
hyporesponsive to donor antigens similar to that of total CD4+ 
T cells (Figure 8B). In contrast, CD4+ T cell responses toward 
third-party antigens increased in the absence of Tregs. Finally, 
we analyzed the coexpression of CD73 and FR4 on graft-
infiltrating CD4+Foxp3− T cells, two markers that have been 
shown to discriminate naïve, effector/memory, and anergic 
CD4+ T cells (16–18). In CD3 Ab-treated tolerant mice, at day 
100 posttransplant (but not at earlier time points, e.g., day 14 
and 28), the CD4+Foxp3− population was highly enriched in 
CD73hiFR4hi T cells (14 vs 6.5% in untreated mice), so identifying 
likely anergic T cells (Figure 8C).
DiscUssiOn
A large body of experimental work in autoimmunity and trans-
plantation has implicated Foxp3+ Tregs in orchestrating and sus-
taining dominant mechanisms of tolerance, allowing a constant 
control of Teff. Data presented in this article support the fact that 
transplant tolerance relies on cell extrinsic and intrinsic mecha-
nisms engaging both FoxP3+ Tregs and CD4+ T cell anergy in a 
timely manner. By using a fully mismatched islet allograft model 
and CD3 Ab therapy, we demonstrated that CTLA-4+Foxp3+ 
Tregs resist depletion by the CD3 Ab, unlike effector alloreactive 
Gzmb+Tbx21+CD4+ Th1 T cells, so enabling them to orchestrate 
the subsequent tolerance inducing events. Even though FoxP3+ 
FigUre 5 | long-term downregulated coexpression of effector genes by individual graft-infiltrating cD4+ T cells after cD3 antibody (ab) therapy. 
C57BL/6 mice were transplanted under the kidney capsule with BALB/c pancreatic islets and treated or not with CD3 Ab F(ab′)2 fragments (50 μg/day for 5 days, 
starting on day 7 posttransplant). Individual CD4+ T cells (n = 72) present within the graft were FACS sorted on day +14 or day +100 posttransplant and subjected 
to multiplex gene expression analysis. (a) Proportion of CD4+ T cells among the 72 cells tested that expressed Gzma, Gzmb, Prf1, Fasl, Tbx21, Il-12rb, and Klrg1 
mRNA in each group. (B) Multifunctionality distribution of intragraft CD4+ T cells. (c) Coexpression of inflammatory and cytotoxic molecules by individual graft-
infiltrating CD4+ T cells. Each row represents one individual cell that is numbered. Each column represents a different gene. For better visualization of coexpression 
patterns, individual cells were ordered by the degree of gene coexpression (Figures 1a,B: χ2 test, *p < 0.05, **p < 0.007, ***p = 0.0007, ***p < 0.0001).  
(D) Intragraft CD4+ T cells were analyzed on day 14 for their capacity to produce IFN-γ and IL-2 following PMA/ionomycin stimulation for 4 h (5–6/group) 
(**p = 0.0043).
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Treg could be found in graft infiltrates indefinitely, treatment 
of hosts maintaining their grafts long term with the PC61 and 
CTLA-4 Abs did not break the tolerant state. Detailed analysis 
of graft-infiltrating T cells was consistent with the alloreactive 
members being anergic.
Our previous work demonstrated the capacity of CD3 Ab to 
induce transplant tolerance (10–12). The therapeutic window was 
of crucial importance, and transplant tolerance was only obtained 
when the treatment was applied at the time of Teff priming to the 
alloantigens. One direct effect of the Ab was a partial and tran-
sient depletion of CD4+ and CD8+ T cells in secondary lymphoid 
organs and in the grafts. Importantly, all T cell subsets were not 
equally sensitive to the CD3 Ab-depleting effect. Single-cell mul-
tiplex PCR, optimized to discriminate T cell heterogeneity and 
functional behavior (19, 20), showed that CD3 Ab preferentially 
targeted and eliminated CD4+ T cells coexpressing Gzmb/Tbx21. 
This finding is reminiscent of our previous report showing that 
cytotoxic intragraft CD8+ T cells coexpressing granzyme B and 
perforin were selectively deleted (13). Apoptosis of these alloreac-
tive T cells by CD3 Abs was mandatory for long-term graft sur-
vival and was dependent on the Fas/FasLigand pathway: in vivo 
FasL blockade abrogated T cell elimination and CD3 Ab-induced 
tolerance to islet transplant (13). In this study, we demonstrated 
that in  vivo, in contrast to Teff, Foxp3+ Tregs were resistant to 
CD3 Ab-mediated depletion. Consequently, their proportion 
increased in both lymphoid organs and the transplanted islets 
at the end of treatment. The molecular mechanisms underlying 
such Treg resistance to apoptosis are not fully understood, but 
may include a reduced expression and activation of signaling 
molecules downstream of the TCR/CD3 complex as well as a 
decreased expression of the CD3 molecules at the cell surface 
compared to CD4+Foxp3− T lymphocytes (21–23).
FigUre 6 | Multiplex gene expression analysis on individual spleen cD4+ T cells after cD3 antibody (ab) therapy. Individual CD4+ T cells (n = 48) were 
sorted on day +14 from the spleen of C57BL/6 mice transplanted with BALB/c islets and treated or not CD3 Ab on day +7 posttransplant. Expression of Gzma, 
Gzmb, Prf1, Fasl, Tbx21, Il-12rb, and Klrg1 mRNA was measured in each cell. Results show the proportion of splenic CD4+ T cells positive for each gene (a), the 
proportion of splenic CD4+ T cells coexpressing zero to three of the selected genes (B) and the coexpression pattern (c) (Figures 3a,B: χ2 test *p = 0,037, 
***p = 0.0002).
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Regulatory T cells are mandatory for the induction of tolerance 
as their depletion at the time of CD3 Ab therapy, or for a short 
time thereafter, abolished long-term graft survival demonstrating 
a critical role of Tregs in that early period when the immune sys-
tem is responding to graft alloantigens. At this time, numerically 
dominant Tregs may influence residual and reconstituting naïve 
T cells inhibiting their differentiation into Th1 effectors. During 
this phase, Tregs from CD3 Ab-treated mice become endowed 
with potent antigen-specific suppressive properties as they 
appeared to inhibit proliferation and IFN-γ secretion of effector 
cells stimulated with donor antigens more efficiently than Tregs 
from untreated recipients, or effector cells specific for third-party 
antigens. CTLA-4 was necessary for Treg-suppressive functions 
as CTLA-4 blockade completely abrogated their inhibitory effect 
in vitro and prevented CD3 Ab-induced tolerance and long-term 
survival in vivo.
Our results are in accordance with many experimental studies 
reporting that Treg depletion (mainly by using the PC61 Ab) 
around the time of grafting prevented the induction of transplant 
tolerance (Table S1 in Supplementary Material). However, very 
few have addressed the impact of Treg elimination once toler-
ance has been established. Surprisingly, in our model, tolerance 
was sustained after administration of PC61 or CTLA-4 Abs on 
day >100 posttransplant, thereby suggesting that long-term 
maintenance of tolerance was not solely dependent on CTLA-
4+Foxp3+ Treg activity. Survival of islet  allografts in Foxp3DTR 
mice after DT injection further supported this point. It was 
possible that other types of regulatory T-cells were operating 
within the graft. For example, IL-10-producing T-cells have been 
implicated in some forms of therapeutic tolerance (24–26). We 
have excluded this by demonstrating that CD3 Ab therapy can 
tolerize even in IL-10 knockout mice (unpublished data). It may 
also be possible that access of long-term tolerated grafts to the 
inhibitory effects of Ab may not be equivalent in the inductive 
and long-term maintenance phases of tolerance.
However, we have provided evidence supporting the notion 
that tolerance maintenance is associated with the persistence of 
CD4+ anergic T cells. First, single-cell multiplex PCR showed 
that, following CD3 Ab-induced apoptosis of alloreactive 
Gzmb+Tbx21+ Th1 cells, most of the remaining CD4+ T cells 
expressed none or only one of the selected inflammatory genes 
over long term, thereby highlighting the absence of potent effec-
tor activity in tolerated grafts. Second, in accordance with PCR 
data, intragraft CD4+ T cells show weak proliferation capacities 
as revealed by the drastically reduced expression of the prolifera-
tion marker Ki67 and of the β subunit of the IL-2 and IL-15 
receptors (CD122) up to day +100 posttransplant. Third, we 
demonstrated that total CD4+ T cells or Treg-deprived CD4+ 
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FigUre 7 | Phenotypic and functional characteristics of intragraft cD4+ T cells after cD3 antibodies (abs) therapy. On day +14 posttransplant, 
pancreatic islet allografts were recovered from C57BL/6 mice treated or not with CD3 Abs (black circles: untreated; gray squares: CD3 Ab treated). Intragraft CD4+ T 
cells were analyzed for their expression of CD44, CD69, CD122, Ki67, and PD-1 (5–15/group) (*p < 0.05, **p < 0.005, ***p < 0.0005).
T cells isolated from tolerant C57BL/6 mice were unable to 
efficiently respond to donor antigen stimulation in contrast to 
third-party antigens, this intrinsic functional unresponsiveness 
being sustained over the long term (>100 days posttransplant). 
Fourth, we observed that tolerated islet grafts harbor a signifi-
cant proportion of CD4+ T-cells exhibiting a Foxp3−CD73hiFR4hi 
phenotype, which has been correlated with an anergic state 
(16–18). Fifth, intragraft CD4+ T cells expressed high levels of 
the inhibitory receptor PD-1, and our recent report showed 
that blocking the PD-1/PD-L1 pathway at the time of CD3 
Ab therapy or at day +100 posttransplant abolished immune 
tolerance and permanent islet graft survival (13). In addition, 
we have recently demonstrated that tolerated islets from CD3 
Ab-treated C57BL/6 mice harbor CD8+ T cells deprived of 
proliferative, inflammatory, or cytotoxic capacities and that 
CD8+ T cell anergy was dependent on the presence of the 
alloantigens and on an in  situ crosstalk between the PD-1/
PD-L1 and TGFβ/TGFβRII pathways (13). This possibility of 
wholesale T-cell anergy can itself be sufficient to explain why 
PC61 and anti-CTLA-4 Abs failed to break the established 
tolerant state. In vivo demonstration of anergy to alloantigens 
has been poorly documented so far. One study in rat models 
showed that long-term survival of renal transplant after donor 
blood administration was associated with the inability of T cells 
to produce IL-2 and to proliferate and that treatment with 
recombinant IL-2 abrogated tolerance (27).
Our data are in line with a recent report documenting in 
type 1 diabetic (T1D) patients treated with humanized CD3 
monoclonal Ab (teplizumab), the presence of dysfunctional 
CD8+ T cells qualified as “exhausted-like” and expressing the 
transcription factor Eomes, TIGIT, and KLRG-1 (28). In our islet 
transplant model, CD8+ T cells from CD3 Ab-treated tolerant 
mice also expressed Eomes and may well correspond to the 
subset described in T1D patients treated with CD3 Abs (13). In 
our model, we use the term “anergy” rather than “exhaustion” for 
both CD4+ and CD8+ T cells to define the unresponsive subsets 
in CD3 Ab-treated mice. In fact, although these cells did not 
respond to donor antigens, they maintained efficient responses 
to third-party antigens or polyclonal stimulus.
In conclusion, this study provides compelling evidence that 
Tregs play a substantive role in establishing a state of tolerance 
but that other mechanisms such as T cell anergy become more 
prominent for its maintenance and for long-term graft survival. 
This does not, of course, rule out a role for Foxp3+ T-cells in 
tolerance maintenance, as the level of their activity may, through 
homeostatic mechanisms, have been adjusted to that correspond-
ing to residual effector function in the treated hosts (29, 30). 
These finding may be of importance for the implementation of 
Treg cell therapy in organ transplantation (31). One key point 
concerns Treg viability and persistence in vivo. In a hematopoietic 
stem cell transplantation clinical trial, infused Tregs were no 
longer detectable in the circulation after 2 weeks (32). It remains 
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FigUre 8 | assessment of cD4+ T cell anergy in tolerant hosts. (a) CD4+ T cells from CD3 antibody (Ab)-treated mice display an impaired antidonor reactivity. 
Spleens were harvested at various time points from C57BL/6 mice transplanted with BALB/c islets and treated or not with CD3 Abs F(ab′)2 fragments. CD4+ T cells 
were purified, and production of IFN-γ was measured by Elispot after a 24-h incubation with irradiated T cell-depleted splenocytes (APC) from BALB/c or C3H 
donors (4–8 mice/group/time point). (B) Antidonor responses of Treg-deprived CD4+CD25− T cells isolated from tolerant CD3 Ab-treated mice (day 100) were 
evaluated by IFN-γ Elispot assay using irradiated BALB/c or third-party (NOD) APCs (n = 5/6) (*p = 0.034). (c) Expression of CD73 and FR4 was analyzed on 
graft-infiltrating CD4+Fox3− T cells recovered from untreated (day 14, n = 5) or CD3 Ab-treated recipients (day 14, n = 4; day 28, n = 4; day 100, n = 8). The mean 
proportion of CD4+Fox3− T cells coexpressing high levels of CD73 and FR4 at day 100 (left panel) is shown as well as representative dot plots of CD73 and FR4 
coexpression pattern (right panel) (**p < 0.009).
unclear whether the infused Tregs had become epigenetically 
destabilized and lost Foxp3 expression, had migrated to tissues, 
or had even died. Nonetheless, our data suggest that infused Tregs 
might enable sufficient immediate control of Teff function around 
the time of transplantation and immunotherapy, so permitting 
diverse intrinsic tolerogenic mechanisms to emerge and deliver 
the maintenance of a life-long tolerant state, with anergy being 
one such dominating mechanism.
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